Tenax Therapeutics Aktie [WKN DE: A12B3H / ISIN: US88032L1008]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Tenax Therapeutics Inc

25.05.22		Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH) (Businesswire)
23.05.22		Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension (Businesswire)
18.05.22		Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules (Businesswire)
31.03.22		Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update (Businesswire)
30.03.22		Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions (Businesswire)
07.07.21		Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules (Businesswire)
10.06.21		Tenax Therapeutics Set to Join Russell Microcap® Index (Businesswire)
17.05.21		Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update (Businesswire)
09.04.21		Tenax Announces Publication Titled "Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ” (Businesswire)
07.04.21		Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders (Businesswire)
31.03.21		Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update (Businesswire)
04.03.21		Tenax Therapeutics to Present at the H.C. Wainwright Global Life Sciences Virtual Conference (Businesswire)
02.03.21		Tenax Therapeutics, Inc. Expands Board of Directors (Businesswire)
20.01.21		Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med (Businesswire)
19.01.21		Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med (Businesswire)
16.11.20		Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update (Businesswire)
10.11.20		Tenax Therapeutics Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020 (Businesswire)
15.10.20		Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation (Businesswire)
02.10.20		Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting (Businesswire)
01.09.20		Tenax Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference (Businesswire)
31.08.20		Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (Businesswire)
17.08.20		Tenax Therapeutics Reports Second Quarter 2020 Results and Provides Business Update (Businesswire)
20.07.20		Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD (Businesswire)
07.07.20		Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules (Businesswire)
03.06.20		Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (Businesswire)
02.06.20		Tenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (Businesswire)
09.04.20		Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 "HELP Study” of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (Businesswire)
12.03.20		Tenax Therapeutics Completes Enrollment in Phase 2 Pulmonary Hypertension Trial (Businesswire)
12.03.20		Tenax Therapeutics Announces $2.75 Million Registered Direct Offering Priced At-the-Market (Businesswire)
21.02.20		Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board (Businesswire)
13.01.20		Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial (Businesswire)
31.10.19		Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial (Businesswire)
29.08.19		Tenax Therapeutics to Present at H.C. Wainwright 21st Annual Global Investment Conference (Businesswire)
23.08.19		Tenax Therapeutics Provides Clinical Development Update (Businesswire)
11.03.19		Tenax Therapeutics Enrolls First Patient for Phase 2 Pulmonary Hypertension Clinical Trial (Businesswire)
04.02.19		Tenax Therapeutics to Present at 2019 BIO CEO & Investor Conference (Businesswire)
04.01.19		Tenax Therapeutics to Present at Biotech Showcase Investor Conference (Businesswire)
11.12.18		Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering (Businesswire)
07.12.18		Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering (Businesswire)
19.11.18		Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial (Businesswire)
20.09.18		Tenax Therapeutics to Present at Upcoming Investor Conferences (Businesswire)
29.08.18		Tenax Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference (Businesswire)
28.08.18		Tenax Therapeutics Announces New Clinical Study Publication Results Indicate Levosimendan Offers Renal Protective Benefits to Heart Failure Patients (Businesswire)
05.06.18		Tenax Therapeutics Announces Appointment of Anthony A. DiTonno as CEO (Businesswire)
01.06.18		Tenax Therapeutics Announces Study Design for Phase 2 Trial of Levosimendan in PH-HFpEF Patients (Businesswire)
04.04.18		Tenax Therapeutics Announces Results of Pre-IND Meeting with FDA for Phase 2 Study of Levosimendan in PH-HFpEF Patients (Businesswire)
14.03.18		Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (Businesswire)
02.03.18		TENX Heartened, AXGN Sees 40% Revenue Growth, Mark Your Calendar For REPH (RTTNews)
01.03.18		Tenax Therapeutics Announces New Scientific Publication of Preclinical Data Provides Additional Evidence of Levosimendan Treatment Effects in Pulmonary Hypertension (Businesswire)
23.02.18		Tenax Therapeutics Announces Reverse Stock Split (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

Nah an 100.000er Marke: Bitcoin, Dogecoin, Ethereum & Co. am Vormittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.11.2024 13:31
Kaufwert:	EUR
	Hinzufügen Speichern